Alligator Bioscience
@AlligatorBio
Followers
398
Following
41
Media
87
Statuses
310
We are an innovative clinical-stage biotechnology company developing tumor-directed immunotherapies for the treatment of cancer.
Lund, Sweden
Joined October 2017
0
1
1
Tune into Episode 55 of the Benchtop Bios Podcast Series, featuring Søren Bregenholt, CEO of @AlligatorBio, who will discuss Alligator’s latest clinical data in the development of tumor-directed immunotherapies. Listen here: https://t.co/e0RA66Qz8Q
0
1
0
Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
news.cision.com
· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 ·
0
0
1
Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022
news.cision.com
· ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB
1
0
6
Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode
news.cision.com
Lund, Sweden, May 9, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the
0
0
2
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
news.cision.com
The English text is an unofficial translation. In case of any discrepancies between the Swedish
0
0
1
Alligator Bioscience AB: Interim report January–March 2022
0
0
2
Invitation to the Presentation of Alligator Bioscience´s Interim Report January - March 2022 on April 27, 2022
news.cision.com
LUND (Sweden) – April 22, 2022 – Alligator Bioscience will host a conference call (in English)
0
0
1
Notice of annual general meeting in Alligator Bioscience AB
news.cision.com
The English text is an unofficial translation. In case of any discrepancies between the Swedish
0
0
1
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
news.cision.com
Lund, Sweden, April 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the
0
0
3
Change in number of shares and votes in Alligator Bioscience AB
news.cision.com
During the month of March, the number of shares and votes in Alligator Bioscience AB have
0
0
0
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
news.cision.com
Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an
0
0
6
Issue and repurchase of series C shares for performance-based share saving program
news.cision.com
Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of
0
0
0
Alligator Bioscience publishes Annual Report for 2021
news.cision.com
Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced
0
0
0
Nomination Committee’s proposal ahead of the AGM 2022 in Alligator Bioscience AB
0
0
1
Invitation to the Presentation of Alligator Bioscience´s Year-End Report January - December 2021 on February 11, 2022
news.cision.com
LUND (Sweden) – February 4, 2022 – Alligator Bioscience will host a conference call (in English)
0
0
1
Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer
news.cision.com
Lund, Sweden, February 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator
0
1
1
Nomination Committee Appointed in Respect of AGM 2022 in Alligator Bioscience AB
news.cision.com
Lund, Sweden, January 20, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator
0
0
1
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
news.cision.com
Lund, Sweden, January 19, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced
0
0
5